Physician profile
Iraj Sabahi
NPI 1881886042
$51,214.10
in general payments reported to CMS, 2019-2025
40 companies · $2,221 in 2025
The $2,221 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $4,530 · 2021: $9,967 · 2022: $18K · 2023: $1,626 · 2024: $1,366 · 2025: $2,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,605 · Consulting Fee: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,605.35 |
| Consulting Fee | $607.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $38,343.68 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $2,559.15 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,602.82 | 2019-2025 | Rinvoq, Skyrizi, Duopa |
| Mallinckrodt Hospital Products INC. | $1,119.58 | 2020-2025 | Acthar |
| Amgen INC. | $1,100.53 | 2019-2025 | Evenity, Prolia, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $965.13 | 2019-2025 | Ofev, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $756.47 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $717.08 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $630.33 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $575.16 | 2019-2025 | |
| Ucb, INC. | $540.52 | 2019-2024 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $340.33 | 2022-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $323.35 | 2021-2025 | Strensiq |
| Corcept Therapeutics | $228.95 | 2019 | |
| Mallinckrodt Enterprises LLC | $207.91 | 2019 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $123.10 | 2019-2023 | Tymlos |
| Hikma Pharmaceuticals USA | $114.37 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.46 | 2021-2022 | |
| Pacira Therapeutics, INC. | $89.11 | 2019-2021 | |
| Gilead Sciences, INC. | $76.50 | 2019-2020 | |
| Octapharma USA, INC. | $75.79 | 2023 | Panzyga, Octagam Immune Globulin (Human) |
| Genentech USA, INC. | $59.66 | 2020-2025 | Gazyva |
| Ani Pharmaceuticals, INC. | $57.78 | 2023-2024 | Purified Cortrophin Gel |
| Fidia Pharma USA INC. | $46.62 | 2025 | Hymovis, Triluron |
| Tersera Therapeutics LLC | $45.63 | 2025 | Quzyttir |
| Lilly USA, LLC | $43.89 | 2023 | Taltz |
| Scilex Pharmaceuticals INC. | $40.44 | 2024-2025 | |
| Antares Pharma, INC. | $39.77 | 2019-2020 | |
| Mindray Ds USA, INC. | $39.62 | 2023 | Te7 Max, Te X |
| Depuy Synthes Sales INC. | $32.50 | 2021 | |
| Biocon Biologics INC | $32.27 | 2024 | Hulio |
| Kyowa Kirin, INC. | $29.73 | 2023 | Crysvita |
| Orthogenrx INC. | $23.20 | 2019 | |
| Bioventus LLC | $21.99 | 2019 | |
| Organon LLC | $21.70 | 2025 | Hadlima |
| Genzyme Corporation | $20.48 | 2023 | |
| Qiagen, LLC | $18.24 | 2022 | |
| Merck Sharp & Dohme LLC | $13.40 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $13.19 | 2023 | |
| Boston Scientific Corporation | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iraj Sabahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.